The Ukrainian government has instigated rapid cost-cutting measures across the drug retail sector, triggered by reports of ...

The pharma and biotech sector has been under pressure since Donald Trump returned to the White House earlier this year.

President Trump threatened to invade Mexico—all in its best interest, of course—in order to smash the drug cartels that are responsible for funneling ...

The day after a shooting on Greenmount Avenue left four people injured, members of the community expressed concerns about the ...

The state’s second-largest insurer is grappling with heightened health care spending and a market that is increasingly unable ...

The impact be especially strong on users of some formulations of testosterone, an antidepressant and an anti-brain-bleed drug ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Morepen Laboratories has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for its Loratadine (anti-allergy API). This marks a ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

No matter how high the inflation is, their demand is inelastic. No matter how slow the current profit growth is, these companies spend on research and development (R&D) for future growth.

Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS” or the "Company”), a medical technology company delivering intelligent, ...